Listed

Celldex Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2011

Filed with the SEC on Aug 4, 2011 and accepted by EDGAR at Aug 4, 2011, 14:20 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2011-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2011-04-01 to 2011-06-30$2.0mus-gaap:Revenues
Revenue6 months2011-01-01 to 2011-06-30$4.5mus-gaap:Revenues
Research and development3 months2011-04-01 to 2011-06-30$7.2mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2011-01-01 to 2011-06-30$14.0mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2011-04-01 to 2011-06-30−$9.9mus-gaap:OperatingIncomeLoss
Operating income6 months2011-01-01 to 2011-06-30−$19.5mus-gaap:OperatingIncomeLoss
Interest expense3 months2011-04-01 to 2011-06-30$434.0kus-gaap:InterestExpense
Interest expense6 months2011-01-01 to 2011-06-30$920.0kus-gaap:InterestExpense
Net income3 months2011-04-01 to 2011-06-30−$10.2mus-gaap:ProfitLoss
Net income6 months2011-01-01 to 2011-06-30−$20.3mus-gaap:ProfitLoss
Diluted EPS3 months2011-04-01 to 2011-06-30−$0.27us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2011-01-01 to 2011-06-30−$0.58us-gaap:EarningsPerShareBasicAndDiluted
Diluted shares (weighted)3 months2011-04-01 to 2011-06-3037,463,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2011-01-01 to 2011-06-3034,770,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2011-01-01 to 2011-06-30−$18.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2011-01-01 to 2011-06-30$282.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2011-06-30$10.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2011-06-30$73.3mus-gaap:AssetsCurrent
Total assetsAt period end2011-06-30$118.5mus-gaap:Assets
Current liabilitiesAt period end2011-06-30$10.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2011-06-30$26.5mus-gaap:Liabilities
Shareholders' equityAt period end2011-06-30$92.0mus-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Source: SEC EDGAR, the filing index for accession 0001104659-11-043630. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.